Startseite › Chronische lymphatische Leukämie › Ohio › Columbus
Klinische Studien zu Chronische lymphatische Leukämie in Columbus, OH
28 Studien zu Chronische lymphatische Leukämie suchen Teilnehmer an Standorten in und um Columbus (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Teilnehmer gesuchtPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- und 8 weitere
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- und 8 weitere
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Teilnehmer gesuchtPhase 3
- Study Site 104, Columbus
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Teilnehmer gesuchtPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Teilnehmer gesuchtPhase 2
- The Ohio State University, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Teilnehmer gesuchtPhase 1/2
- Research Site, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 1
- The James Cancer Hospital and Solove Research Institute, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Teilnehmer gesuchtPhase 3
- OSU Comprehensive Cancer Center, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Teilnehmer gesuchtPhase 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Teilnehmer gesuchtPhase 1
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Teilnehmer gesuchtPhase 1
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Teilnehmer gesuchtPhase 1
- The Ohio State University, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Teilnehmer gesuchtPhase 4
- Ohio State University Comprehensive Cancer Center, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Teilnehmer gesuchtPhase 4
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
Teilnehmer gesuchtPhase 1
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Teilnehmer gesuchtPhase 2
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Teilnehmer gesuchtPhase 2
- The Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Teilnehmer gesuchtPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Teilnehmer gesuchtPhase 1
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
HPC Offered for PRESERVE Expansion
Teilnehmer gesuchtBeobachtungsstudie
- The Ohio State University Medical Center, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Teilnehmer gesuchtPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Chronische lymphatische Leukämie-Studien in anderen Städten
- Boston, MA31 Studien
- Durham, NC27 Studien
- Washington, DC22 Studien
- Seattle, WA20 Studien
- Rochester, MN19 Studien
- New York City, NY18 Studien
- Houston, TX17 Studien
- Baldwin Park, CA16 Studien
- Milwaukee, WI15 Studien
- Chicago, IL14 Studien
- Cincinnati, OH14 Studien
- Nashville, TN13 Studien
Weitere Studien in Columbus
- Nichtkleinzelliges Lungenkarzinom56 Studien
- Brustkrebs39 Studien
- Eierstockkrebs39 Studien
- Krebs (alle Arten)38 Studien
- Lungenkrebs37 Studien
- Akute myeloische Leukämie35 Studien
- Metastasierender Krebs27 Studien
- Endometriumkarzinom25 Studien
- Kolorektales Karzinom24 Studien
- Prostatakrebs24 Studien
- Multiples Myelom24 Studien
- Melanom21 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.